Strata Critical Medical (SRTA) presented its growth trajectory at the Jefferies Healthcare Services and Technology Conference on September 14, 2026. The company reported a 3.75% increase in its stock price to $5.39, with a 52-week range of $3.95 to $6.50 and a market capitalization of $476 million. Analysts forecast a price target range of $8 to $12.75 and an EPS of $0.03 for 2026.
Strata serves over 250 hospitals across the U.S., holding a one-third market share in organ logistics. The company owns 10 aircraft, with the remaining 30% supplied by third-party operators. It serves about 250 transplant centers and 50 Organ Procurement Organizations (OPOs).
The organ transplant industry faces significant challenges, with about 15 people dying daily in the U.S. waiting for organs. The wait list stands at 100,000 people, with millions more potentially eligible. Donation after Circulatory Death (DCD) is growing at over 20% annually and now accounts for more than half of donations in the U.S. The average donor-recipient distance has increased by over 60% across organ types.
Strata's Normothermic Regional Perfusion (NRP) technology has seen penetration rise from 20% to 60% in recent months, increasing the average number of usable organs per donor from 1.7 to 2.6. The company can deliver services locally in two-thirds of cases. The clinical transplant business grew over 20% quarter-over-quarter from Q1 to Q2 2026, with a gross profit margin of 30% and free cash flow conversion from EBITDA above 90%.
Strata reported a 67% revenue growth over the last twelve months, with EBITDA at $7.2 million. The company expects high-teens organic growth, plus another 10 percentage points from acquisitions. Year-to-date 2026 acquisitions have added about $6 million of adjusted EBITDA, including Louisville Perfusion Services ($3 million), a surgical recovery provider, and an organ placement provider. Acquisitions were completed at mid-single-digit multiples of free cash flow.
